Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury

Abstract

Closed isolated traumatic brain injury (ТBI) is a major medical and social problem due to its high prevalence, high rates of mortality and disability, as well as the economic costs of treatment, rehabilitation and social assistance to victims [1]. Considering the severity of this disease and the insufficient effectiveness of conventional methods of treatment, we studied the effectiveness of the drug Kallidinogenase (tissue kallikrein) in complex therapy in patients with closed isolated traumatic brain injury.